Related Experiment Video
Updated: May 3, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Targeting the XIAP/caspase-7 complex selectively kills caspase-3-deficient malignancies
Yuan-Feng Lin1, Tsung-Ching Lai, Chih-Kang Chang
1Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan.
Abstract:
Caspase-3 downregulation (CASP3/DR) in tumors frequently confers resistance to cancer therapy and is significantly correlated with a poor prognosis in cancer patients. Because CASP3/DR cancer cells rely heavily on the activity of caspase-7 (CASP7) to initiate apoptosis, inhibition of activated CASP7 (p19/p12-CASP7) by X-linked inhibitor of apoptosis protein (XIAP) is a potential mechanism by which apoptosis is prevented in those cancer cells. Here, we identify the pocket surrounding the Cys246 residue of p19/p12-CASP7 as a target for the development of a protein-protein interaction (PPI) inhibitor of the XIAP:p19/p12-CASP7 complex. Interrupting this PPI directly triggered CASP7-dependent apoptotic signaling that bypassed the activation of the apical caspases and selectively killed CASP3/DR malignancies in vitro and in vivo without adverse side effects in nontumor cells. Importantly, CASP3/DR combined with p19/p12-CASP7 accumulation correlated with the aggressive evolution of clinical malignancies and a poor prognosis in cancer patients. Moreover, targeting of this PPI effectively killed cancer cells with multidrug resistance due to microRNA let-7a-1-mediated CASP3/DR and resensitized cancer cells to chemotherapy-induced apoptosis. These findings not only provide an opportunity to treat CASP3/DR malignancies by targeting the XIAP:p19/p12-CASP7 complex, but also elucidate the molecular mechanism underlying CASP3/DR in cancers.
Insights
Targeting the XIAP:CASP7 interaction can kill cancer cells lacking Caspase-3 (CASP3/DR) and overcome drug resistance. This approach triggers apoptosis, offering a new strategy for treating aggressive malignancies.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Caspase-3 downregulation (CASP3/DR) in tumors leads to therapy resistance and poor prognosis.
- CASP3/DR cancer cells depend on caspase-7 (CASP7) for apoptosis, and XIAP inhibits activated CASP7 (p19/p12-CASP7).
Purpose of the Study:
- To identify a therapeutic target to overcome CASP3/DR-mediated resistance.
- To develop a protein-protein interaction (PPI) inhibitor for the XIAP:p19/p12-CASP7 complex.
Main Methods:
- Identified the Cys246 residue pocket on p19/p12-CASP7 as a target for PPI inhibition.
- Developed and tested a novel PPI inhibitor in vitro and in vivo.
- Investigated the role of microRNA let-7a-1 in mediating CASP3/DR.
Main Results:
- Inhibition of the XIAP:p19/p12-CASP7 PPI triggered CASP7-dependent apoptosis, selectively killing CASP3/DR tumors.
- Treatment showed no adverse effects on non-tumor cells.
- Targeting this PPI overcame multidrug resistance and resensitized cells to chemotherapy.
- CASP3/DR and p19/p12-CASP7 accumulation correlated with aggressive cancers and poor patient prognosis.
Conclusions:
- Targeting the XIAP:p19/p12-CASP7 complex offers a novel therapeutic strategy for CASP3/DR malignancies.
- This approach bypasses apical caspases and selectively eliminates resistant cancer cells.
- Findings elucidate the mechanism of CASP3/DR in cancer progression and resistance.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Caspases
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
CRISPR/Cas9 Genome Editing

